Function of proprotein convertase subtilisin/kexin type 9 and its role in central nervous system diseases: An update on clinical evidence
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has attracted lots of attention in preventing the clearance of plasma low-density lipoprotein cholesterol (LDL-C). PCSK9 inhibitors are developed to primarily reduce the cardiovascular risk by lowering LDL-C level. Recently, a number of pleiotropic extrahepatic functions of PCSK9 beyond the regulation of cholesterol metabolism, particularly its effects on central nervous system (CNS) diseases have been increasingly identified. Emerging clinical evidence have revealed that PCSK9 may play a significant role in neurocognition, depression, Alzheimer's disease, and stroke. The focus of this review is to elucidate the functions of PCSK9 and highlight the effects of PCSK9 in CNS diseases, with the aim of identifying the potential risks that may arise from low PCSK9 level (variant or inhibitor) in the clinical practice.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other studies show the potential risks that may arise from low PCSK9 level (variant or inhibitor) for central nervous system diseases including AD.
“other studies show the potential risks that may arise from low PCSK9 level (variant or inhibitor) for central nervous system (CNS) diseases including AD [21].”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an <i>APOE</i> Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [21]
PCSK9 inhibitors may be harmful for AD in the minor frequencies of some PCSK9 genotypes.
“PCSK9 inhibitors may be harmful for AD in the minor frequencies of some PCSK9 genotypes [21, 24].”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an <i>APOE</i> Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [21]
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · see citing works
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · see citing works
Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2017) · BMJ · doi:10.1136/bmj.j1648 · Cited by 178 · see citing works
Lipid lowering and Alzheimer disease risk: A mendelian randomization study
Williams, D. M., Finan, C., Schmidt, A. F., Burgess, S., & Hingorani, A. D. (2020) · Annals of Neurology · doi:10.1002/ana.25642 · Cited by 157 · see citing works
Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function
Rosoff, D. B., Bell, A. S., Jung, J., Wagner, J., Mavromatis, L. A., & Lohoff, F. W. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.05.041 · Cited by 126 · see citing works
Kent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., et al. (2017) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001632 · Cited by 86 · see citing works
Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease
Zimetti, F., Caffarra, P., Ronda, N., Favari, E., Adorni, M. P., Zanotti, I., Bernini, F., Barocco, F., Spallazzi, M., Galimberti, D., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160411 · Cited by 75 · see citing works
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67 · see citing works
Yuet, W. C., Ebert, D., & Jann, M. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620959271 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tao, Q., Ang, T. F. A., Huang, J., Itchapurapu, I. S., Mez, J., Alosco, M., Au, R., Farrer, L. A., Zhang, X., Qiu, W. Q., et al. (2026) · Health Science Reports · doi:10.1002/hsr2.71810 · Cited by 1 · see citing works
- Authors
- Zhu, X., Xu, Y., Li, L., Sun, J., Wang, Y., Chen, J., Wang, C., Zhang, S., & Jin, L.
- Affiliations
- Department of Pharmacy, Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou China
- Wenzhou Medical University (CN)
- Department of Pharmacy Deqing People's Hospital Huzhou China
- Sir Run Run Shaw Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
- Hangzhou Xixi hospital (CN)
- Corresponding author
- Jin, Liang‐Yan
- ORCID
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 2023-11-09
- Volume
- 85
- Issue
- 1
- Pages
- e22131-e22131
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W4388522965
- Cited by
- 5
- References
- 9
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2
- FWCI
- 0.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Development Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
- Keywords
- PCSK9, PCSK9 inhibitors, central nervous system disorders, neurocognitive function, depression, Alzheimer's disease, stroke, LDL cholesterol, cholesterol metabolism, pleiotropy, cardiovascular risk
- MeSH terms
- Proprotein Convertase 9, Central Nervous System Diseases, Humans, Cholesterol, LDL, Subtilisins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
